89bio Inc (ETNB)
8.75
-0.16
(-1.85%)
USD |
NASDAQ |
Nov 14, 16:00
8.50
-0.25
(-2.86%)
After-Hours: 20:00
89bio Research and Development Expense (Quarterly): 141.44M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 141.44M |
| June 30, 2024 | 44.86M |
| March 31, 2024 | 47.43M |
| December 31, 2023 | 33.59M |
| September 30, 2023 | 31.42M |
| June 30, 2023 | 34.92M |
| March 31, 2023 | 22.31M |
| December 31, 2022 | 19.06M |
| September 30, 2022 | 22.20M |
| June 30, 2022 | 19.69M |
| March 31, 2022 | 19.85M |
| December 31, 2021 | 20.98M |
| September 30, 2021 | 23.59M |
| Date | Value |
|---|---|
| June 30, 2021 | 15.63M |
| March 31, 2021 | 10.13M |
| December 31, 2020 | 8.77M |
| September 30, 2020 | 11.21M |
| June 30, 2020 | 8.443M |
| March 31, 2020 | 7.778M |
| December 31, 2019 | 7.192M |
| September 30, 2019 | 6.68M |
| June 30, 2019 | 3.165M |
| March 31, 2019 | 4.309M |
| December 31, 2018 | 3.692M |
| September 30, 2018 | 3.289M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
7.192M
Minimum
Dec 2019
141.44M
Maximum
Sep 2024
27.52M
Average
20.41M
Median
Research and Development Expense (Quarterly) Benchmarks
| Madrigal Pharmaceuticals Inc | 68.74M |
| Eli Lilly and Co | 2.734B |
| Viking Therapeutics Inc | 22.78M |
| Akero Therapeutics Inc | 72.23M |
| NovaBay Pharmaceuticals Inc | 0.004M |